UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Response of refractory colitis to intravenous or oral tacrolimus (FK506)

Inflammatory bowel diseases, 2002-09, Vol.8 (5), p.317-324

2002

Volltextzugriff (PDF)

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 Versus prednisolone in active crohn's disease

The American journal of gastroenterology, 2006-04, Vol.101 (4), p.793-797

2006

Volltextzugriff (PDF)

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

Journal of viral hepatitis, 2010-07, Vol.17 (7), p.459-468

2010

Volltextzugriff (PDF)

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy

Journal of viral hepatitis, 2011-04, Vol.18 (4), p.e81-e90

2011

Volltextzugriff (PDF)

[655] PEG-IFN ALFA-2a PLUS RIBAVIRIN IS SUPERIOR COMPARED TO HIGH DOSE CONSENSUS INTERFERON (CIFN) AND RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

Journal of hepatology, 2007-04, Vol.46, p.S248-S248

2007

Volltextzugriff (PDF)

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

Clinical and experimental immunology, 1993-10, Vol.94 (1), p.174-181

1993

Volltextzugriff (PDF)

1149 PREDICTIVE FACTORS FOR NONRESPONSE IN GENOTYPE 2/3 INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE SETTING

Journal of hepatology, 2012-04, Vol.56, p.S454-S454

2012

Volltextzugriff (PDF)

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

Journal of viral hepatitis, 2012-02, Vol.19 (2), p.e120-e125

2012

Volltextzugriff (PDF)

435 TREATMENT OF HCV GENOTYPE 3 (GT3)-INFECTION WITH PEG-IFN A-2B AND RIBAVIRIN (RBV): AGE RELATED DIFFERENCES IN SVR AND RELAPSE

Journal of hepatology, 2011-03, Vol.54, p.S177-S177

2011

Volltextzugriff (PDF)

404 DOSE REDUCTION OF PEGINTERFERON ALFA-2A (PEG) IN COMBINATION WITH RIBAVIRIN (RBV) IN CHRONIC HEPATITIS C (CHC) PATIENTS: IMPACT ON VIROLOGICAL RESPONSE UNDER REAL LIFE CONDITIONS

Journal of hepatology, 2011-03, Vol.54, p.S162-S162

2011

Volltextzugriff (PDF)

447 DIFFERENCES IN DEMOGRAPHICS AND TREATMENT OUTCOME OF CHRONIC HEPATITIS C (CHC) PATIENTS OF DIFFERENT EUROPEAN ORIGIN TREATED WITH PEGINTERFERON ALFA-2A (40KDA) AND RIBAVIRIN (PEG/RBV)

Journal of hepatology, 2011-03, Vol.54, p.S182-S182

2011

Volltextzugriff (PDF)

309 COMPARISON OF EFFICACY BETWEEN PEGINTERFERON ALFA-2A OR −2B PLUS RIBAVIRINE IN THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN DAILY ROUTINE: RESULTS FROM PRACTICE

Journal of hepatology, 2010, Vol.52, p.S130-S130

2010

Volltextzugriff (PDF)

Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease

Clinical and experimental immunology, 2008-06, Vol.94 (1), p.174-181

2008

Volltextzugriff (PDF)

[226] LONG-TERM TREATMENT WITH PEG-IFN-ALFAb REDUCES HEPATOCELLULAR INCIDENCE AND PREVENTS CLINICAL COMPLICATIONS IN HEPATITIS C CIRRHOSIS - AN INTERIM ANALYSIS OF A MULTICENTER TRIAL

Journal of hepatology, 2007, Vol.46, p.S93-S93

2007

Volltextzugriff (PDF)

ASCA and pANCA serum levels are no reliable markers to differentiate between Crohns disease and ulcerative colitis - a retrospective analysis: P-068

Inflammatory bowel diseases, 2008-02, Vol.14, p.S30

Witthoeft, T

2008

Volltextzugriff (PDF)

Dexamethasone induced upregulation of human beta-defensin-2 (HBD2) mRNA expression in human colonic epithelial cells: P-102

Inflammatory bowel diseases, 2008-02, Vol.14, p.S37

Witthoeft, T

2008

Volltextzugriff (PDF)

Dexamethasone induced upregulation of human beta-defensin-2 (HBD2) mRNA expression in human colonic epithelial cells: P-102

Inflammatory bowel diseases, 2008-01, Vol.14, p.S38

Witthoeft, T

2008

Volltextzugriff (PDF)

840 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY

Journal of hepatology, 2008, Vol.48, p.S315-S315

2008

Volltextzugriff (PDF)

811 ESTIMATING THE LIKELIHOOD OF SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C (CHC) THERAPY

Journal of hepatology, 2008, Vol.48, p.S303-S304

2008

Volltextzugriff (PDF)

812 THE ROLE OF CHOLESTEROL ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN THE TREATMENT OF GENOTYPE-1 INFECTED HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON-ALFA-2A (PEG) AND RIBAVIRIN (RBV)

Journal of hepatology, 2008, Vol.48, p.S304-S304

2008

Volltextzugriff (PDF)

842 EFFICACY AND TOLERABILITY OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN GENOTYPE 4 PATIENTS WITH CHRONIC HEPATITIS C (CHC) UNDER REAL LIFE CONDITIONS

Journal of hepatology, 2008, Vol.48, p.S316-S316

2008

Volltextzugriff (PDF)

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2013-08, Vol.369 (8), p.699-710

2013

Volltextzugriff (PDF)

Use of the serum detection of Anti-Saccharomyces Cerevisiae Antibodies, Perinu-clear Antineutrophil Cytoplasmic Antibodies and antibodies against the exocrine pancreas and intestinal goblet cells to differentiate between Crohnʼs Disease and Ulcerative: O-0027

Inflammatory bowel diseases, 2008-12, Vol.14, p.S9

2008

Volltextzugriff (PDF)

Use of the serum detection of Anti-Saccharomyces Cerevisiae Antibodies, Perinuclear Antineutrophil Cytoplasmic Antibodies and antibodies against the exocrine pancreas and intestinal goblet cells to differentiate between Crohnʼs Disease and Ulcerative: O-0027

Inflammatory bowel diseases, 2008-12, Vol.14, p.S9

2008

Volltextzugriff (PDF)

Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease

Transplantation proceedings, 2001-05, Vol.33 (3), p.2247-2248

2001

Volltextzugriff (PDF)

1 – 25 von 366

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(342)
Mit Volltextzugriff
(294)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(200)
Life Sciences & Biomedicine
(142)
Social Sciences
(116)
Psychology
(112)
Humans
(107)
Female
(80)
Psychiatry
(78)
Male
(77)
Psychology, Clinical
(77)
Adult
(71)
Physical Sciences
(47)
Anxiety
(42)
Middle Aged
(42)
Physics
(38)
Biological And Medical Sciences
(36)
Surveys And Questionnaires
(31)
Health Anxiety
(30)
Medical Sciences
(27)
Medically Unexplained Symptoms
(25)
Psychology. Psychoanalysis. Psychiatry
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Response of refractory colitis to intravenous or oral tacrolimus (FK506)

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 Versus prednisolone in active crohn's disease

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy

[655] PEG-IFN ALFA-2a PLUS RIBAVIRIN IS SUPERIOR COMPARED TO HIGH DOSE CONSENSUS INTERFERON (CIFN) AND RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

1149 PREDICTIVE FACTORS FOR NONRESPONSE IN GENOTYPE 2/3 INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE SETTING

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

435 TREATMENT OF HCV GENOTYPE 3 (GT3)-INFECTION WITH PEG-IFN A-2B AND RIBAVIRIN (RBV): AGE RELATED DIFFERENCES IN SVR AND RELAPSE

404 DOSE REDUCTION OF PEGINTERFERON ALFA-2A (PEG) IN COMBINATION WITH RIBAVIRIN (RBV) IN CHRONIC HEPATITIS C (CHC) PATIENTS: IMPACT ON VIROLOGICAL RESPONSE UNDER REAL LIFE CONDITIONS

447 DIFFERENCES IN DEMOGRAPHICS AND TREATMENT OUTCOME OF CHRONIC HEPATITIS C (CHC) PATIENTS OF DIFFERENT EUROPEAN ORIGIN TREATED WITH PEGINTERFERON ALFA-2A (40KDA) AND RIBAVIRIN (PEG/RBV)

309 COMPARISON OF EFFICACY BETWEEN PEGINTERFERON ALFA-2A OR −2B PLUS RIBAVIRINE IN THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN DAILY ROUTINE: RESULTS FROM PRACTICE

Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease

[226] LONG-TERM TREATMENT WITH PEG-IFN-ALFAb REDUCES HEPATOCELLULAR INCIDENCE AND PREVENTS CLINICAL COMPLICATIONS IN HEPATITIS C CIRRHOSIS - AN INTERIM ANALYSIS OF A MULTICENTER TRIAL

ASCA and pANCA serum levels are no reliable markers to differentiate between Crohns disease and ulcerative colitis - a retrospective analysis: P-068

Dexamethasone induced upregulation of human beta-defensin-2 (HBD2) mRNA expression in human colonic epithelial cells: P-102

Dexamethasone induced upregulation of human beta-defensin-2 (HBD2) mRNA expression in human colonic epithelial cells: P-102

840 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY

811 ESTIMATING THE LIKELIHOOD OF SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C (CHC) THERAPY

812 THE ROLE OF CHOLESTEROL ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN THE TREATMENT OF GENOTYPE-1 INFECTED HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON-ALFA-2A (PEG) AND RIBAVIRIN (RBV)

842 EFFICACY AND TOLERABILITY OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN GENOTYPE 4 PATIENTS WITH CHRONIC HEPATITIS C (CHC) UNDER REAL LIFE CONDITIONS

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Use of the serum detection of Anti-Saccharomyces Cerevisiae Antibodies, Perinu-clear Antineutrophil Cytoplasmic Antibodies and antibodies against the exocrine pancreas and intestinal goblet cells to differentiate between Crohnʼs Disease and Ulcerative: O-0027

Use of the serum detection of Anti-Saccharomyces Cerevisiae Antibodies, Perinuclear Antineutrophil Cytoplasmic Antibodies and antibodies against the exocrine pancreas and intestinal goblet cells to differentiate between Crohnʼs Disease and Ulcerative: O-0027

Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease

Suchergebnisse filtern